Radiant Energy Vacuum (REV) has developed a new dehydration technology that can efficiently dry foods, liquids, and pharmaceuticals using less energy than traditional methods, and they are partnering with large multinational companies like Nestlé, Danisco, and Bimbo to commercialize the technology through licensing agreements and machine sales that could generate over $50 million annually per partner. REV aims to establish this new dehydration platform globally through strategic collaborations to test and refine the technology while building a portfolio of patents and royalty revenue streams.
"Collaboration in the Meltdown" is part of the MaRS CIBC Presents Entrepreneurship 101 lecture series.
Speaker: John Abele
January 7, 2009
More information including video podcast: http://www.marsdd.com/Events/Event-Calendar/Ent101/2009/lived-it-lecture-01072009.html
Many technology ventures are focused on securing funds from venture capitalists (VCs). This lecture focuses on understanding the motivation of private venture capital firms and how it affects the structure of their term sheets and legal agreements. We explore common pitfalls in dealing with VCs, as well as success stories regarding VC investment.
Part of Entrepreneurship 101
http://www.marsdd.com/events/details.html?uuid=aed97387-fb20-4779-a111-17fb9c5428d0
This lecture covers the human resources policies and practices needed in an entrepreneurial context, including everyone's favorite HR topics: hiring and firing! Find out why it’s so important to plan your human resources early on in the start-up process. Look at the legalities of hiring employees, the process of recruiting and how to manage and pay employees.
http://www.marsdd.com/events/details.html?uuid=0cbcbdaa-5d76-442e-861e-7012eb62a403
Novel biomarkers for diagnostics and drug R&D: What is industry looking for?MaRS Discovery District
Tom Metcalfe of F. Hoffmann-La Roche AG talks about what the pharmaceutical industry is looking for in novel biomarkers for diagnostics and drug research and development.
Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
"Collaboration in the Meltdown" is part of the MaRS CIBC Presents Entrepreneurship 101 lecture series.
Speaker: John Abele
January 7, 2009
More information including video podcast: http://www.marsdd.com/Events/Event-Calendar/Ent101/2009/lived-it-lecture-01072009.html
Many technology ventures are focused on securing funds from venture capitalists (VCs). This lecture focuses on understanding the motivation of private venture capital firms and how it affects the structure of their term sheets and legal agreements. We explore common pitfalls in dealing with VCs, as well as success stories regarding VC investment.
Part of Entrepreneurship 101
http://www.marsdd.com/events/details.html?uuid=aed97387-fb20-4779-a111-17fb9c5428d0
This lecture covers the human resources policies and practices needed in an entrepreneurial context, including everyone's favorite HR topics: hiring and firing! Find out why it’s so important to plan your human resources early on in the start-up process. Look at the legalities of hiring employees, the process of recruiting and how to manage and pay employees.
http://www.marsdd.com/events/details.html?uuid=0cbcbdaa-5d76-442e-861e-7012eb62a403
Novel biomarkers for diagnostics and drug R&D: What is industry looking for?MaRS Discovery District
Tom Metcalfe of F. Hoffmann-La Roche AG talks about what the pharmaceutical industry is looking for in novel biomarkers for diagnostics and drug research and development.
Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
A Step-by Step Guide to Starting a Nanotech Business
Objective: To build a viable business selling nanotechnology to make profit
How to:
1. Set up your nanotech business structure.
2. Raise financing, receive government grants and tax breaks.
3. Hire developers, employees, subcontractors and suppliers.
4. Protect ownership of your intellectual property in nanotechnology.
5. Use open innovation to enhance R&D.
6. Commercialize your nanotechnology by licensing and distribution.
Discussion about the pharmaceutical licencing process and different steps involved in the process, current trends in licencing process and types of licences.
The value of any technological innovation is only partly determined by what the tech-nology can do. A large part of the value of an innovation is determined by the degree to which people can understand it, access it, and integrate it within their lives. Effective deployment strategies can reduce uncertainty about the product, lower resistance to switching from competing or substitute goods, and accelerate adoption.
Intangible assets, which account for up to 90% of a company's value, especially patents, which make up the largest proportion of these assets, are hardly ever utilized for corporate value creation despite their value. In this presentation, I introduce patent management solutions for the development of patents that can contribute to corporate value creation, using the latest digital technologies such as AI, blockchain, and Web 3.0. I also introduce measures to maximize the financial use of patent assets secured through such patent management. In particular, I will look into the domestic and overseas trends of STO (Security Token Offering), which have recently been gaining attention in S. Korea, and learn about strategies and methods for patent asset STO.
Presentation on the importance of commercialisation, the VITALISE Innovation and Commercialisation Monitoring System, the EU Innovation Radar Platform, the KTH Innovation Readiness Model, and the case study of HearArt Technologies in the commercialisation process.
SME patent pooling
Korea Federation of Small & Medium Enterprises (SME’s)
Government support to SME’s
SME’s Deal with large Companies
Pros and Cons- SME’s Patent Pool
WHO Patent Pool
The Intellectual Property Consultancy, run by entrepreneurs, for entrepreneurs. Providing patent planning, optimisation and management services, to start-ups, SMEs and investors. Covering initial (pre-filing) prior art search, market need validation, geography selection, portfolio management and more. Based on over 30 years' experience in technology R&D and IP planning & management. Free initial consultation. UK-based.
Commercialising quantum technology, Competition briefing - Chris Jones, Innov...KTN
As part of the Industrial Strategy the Government will invest in the “Commercialising quantum technologies” Industrial Strategy Challenge Fund (ISCF) to enable the UK to lead the global development and application of quantum technologies.
The aim of the competition is to advance the commercialisation of quantum technologies in the UK through the investment of up to £27m in innovation projects.
The webcast recording is now available. Click here to watch it: https://www.youtube.com/watch?v=8beNopMS7sw
Find out more about the Quantum Technologies Special Interest Group at https://ktn-uk.co.uk/interests/quantum-technologies
Join the Quantum Technologies Special Interest Group at https://www.linkedin.com/groups/8594516/
Don Tapscott's New Solutions for a Connected Planet - MaRS Global LeadershipMaRS Discovery District
In this new age of networked intelligence, collaborative communities are enhancing and even bypassing crumbling institutions. We are innovating the way our financial institutions and governments operate; how we educate our children; how the healthcare, newspaper, and energy industries serve their customers; how we care for our neighbourhoods; and even how we solve global problems.
From his latest book, (co-author Anthony D. Williams) Macrowikinomics: New Solutions for a Connected Planet, Don Tapscott presents groundbreaking innovations from every corner of the globe: how businesses, organizations and individuals alike are using mass collaboration to revolutionize not only the way we work, but how we live, learn, create and care for each other.
A Step-by Step Guide to Starting a Nanotech Business
Objective: To build a viable business selling nanotechnology to make profit
How to:
1. Set up your nanotech business structure.
2. Raise financing, receive government grants and tax breaks.
3. Hire developers, employees, subcontractors and suppliers.
4. Protect ownership of your intellectual property in nanotechnology.
5. Use open innovation to enhance R&D.
6. Commercialize your nanotechnology by licensing and distribution.
Discussion about the pharmaceutical licencing process and different steps involved in the process, current trends in licencing process and types of licences.
The value of any technological innovation is only partly determined by what the tech-nology can do. A large part of the value of an innovation is determined by the degree to which people can understand it, access it, and integrate it within their lives. Effective deployment strategies can reduce uncertainty about the product, lower resistance to switching from competing or substitute goods, and accelerate adoption.
Intangible assets, which account for up to 90% of a company's value, especially patents, which make up the largest proportion of these assets, are hardly ever utilized for corporate value creation despite their value. In this presentation, I introduce patent management solutions for the development of patents that can contribute to corporate value creation, using the latest digital technologies such as AI, blockchain, and Web 3.0. I also introduce measures to maximize the financial use of patent assets secured through such patent management. In particular, I will look into the domestic and overseas trends of STO (Security Token Offering), which have recently been gaining attention in S. Korea, and learn about strategies and methods for patent asset STO.
Presentation on the importance of commercialisation, the VITALISE Innovation and Commercialisation Monitoring System, the EU Innovation Radar Platform, the KTH Innovation Readiness Model, and the case study of HearArt Technologies in the commercialisation process.
SME patent pooling
Korea Federation of Small & Medium Enterprises (SME’s)
Government support to SME’s
SME’s Deal with large Companies
Pros and Cons- SME’s Patent Pool
WHO Patent Pool
The Intellectual Property Consultancy, run by entrepreneurs, for entrepreneurs. Providing patent planning, optimisation and management services, to start-ups, SMEs and investors. Covering initial (pre-filing) prior art search, market need validation, geography selection, portfolio management and more. Based on over 30 years' experience in technology R&D and IP planning & management. Free initial consultation. UK-based.
Commercialising quantum technology, Competition briefing - Chris Jones, Innov...KTN
As part of the Industrial Strategy the Government will invest in the “Commercialising quantum technologies” Industrial Strategy Challenge Fund (ISCF) to enable the UK to lead the global development and application of quantum technologies.
The aim of the competition is to advance the commercialisation of quantum technologies in the UK through the investment of up to £27m in innovation projects.
The webcast recording is now available. Click here to watch it: https://www.youtube.com/watch?v=8beNopMS7sw
Find out more about the Quantum Technologies Special Interest Group at https://ktn-uk.co.uk/interests/quantum-technologies
Join the Quantum Technologies Special Interest Group at https://www.linkedin.com/groups/8594516/
Don Tapscott's New Solutions for a Connected Planet - MaRS Global LeadershipMaRS Discovery District
In this new age of networked intelligence, collaborative communities are enhancing and even bypassing crumbling institutions. We are innovating the way our financial institutions and governments operate; how we educate our children; how the healthcare, newspaper, and energy industries serve their customers; how we care for our neighbourhoods; and even how we solve global problems.
From his latest book, (co-author Anthony D. Williams) Macrowikinomics: New Solutions for a Connected Planet, Don Tapscott presents groundbreaking innovations from every corner of the globe: how businesses, organizations and individuals alike are using mass collaboration to revolutionize not only the way we work, but how we live, learn, create and care for each other.
SR&ED: What you need to know about the changing landscape - MaRS Best PracticesMaRS Discovery District
The Scientific Research and Experimental Development (SR&ED) tax incentive program provides support in the form of tax credits to groups or individuals conducting scientific research or experimental development in Canada.
Some significant changes are on the way as a result of the last federal budget. See how these new rules could affect you!
2. Company Radiant Energy Vacuum (“REV”) Dehydration Technology Vancouver-based industrial technology company, UBC spin-off New proprietary method of drying food, bulk liquids, biological and pharmaceutical material Large, diverse global markets use drying to extend shelf-life, reduce shipping & storage costs, create novel products Mission is to introduce a new global dehydration platform to compete with freeze drying, air drying & spray drying
4. Commercial Progression Technology Development Targets as of January 2011 Commercial machine with dried capacity of up to 100 Kilo per hour sold to CAL-SAN, testing initiated with Nestlé & Bimbo in 2010 Expected time required to complete pilot machine testing, Danisco licence agreement and secure first commercial machine order for delivery in first half of 2012 FDA GMP regulatory approvals required for therapeutic pharmaceutical applications
5. Commercialization Strategy Two tier approach for broader market acceptance Strategic Plan: start with collaborations, build a royalty stream from technology licenses,outsource manufacturing of REV machines Tier One: Strategic collaborations with leading multinationals, exclusive agreements for specific global market segments, targeted annual royalties $25-$50M per division NestléSA, DaniscoAS, Grupo Bimbo SA & Grimmway Farms Tier Two: Entrepreneurial or regional partnerships with limited territory or product exclusivity, targeted annual royalties of $1-$5M per partner CAL-SAN Enterprises, IFS/Smartpac
6. Intellectual Property Strategy Supporting the Strategic Plan ENW owns 7 patents/pending plus exclusive world-wide rights to 7 patents filed by UBC (Dr. Tim Durance): 2016 - 2024 IP protection strategy: patent in big markets where machines are likely to be installed, or product sales may occur - India, China, Brazil, EU and North America, possibly other countries depending on the application PCT route gives 2 ½ years to decide where to file. Start with US provisional while invention is refined, then file PCT within 12 months. ~ 4 months later, the PCT patent examiner conducts search and gives written opinion. National patent filings in selected countries 30 months after the provisional application. Takes a further 1-5 years to obtain patents.
7. Collaborations Give & Take with Tier 1 & Tier 2 Partners Global collaborations help move us along the Technology Adoption Life Cycle* (innovators, early adopters, early majority, late majority, laggards): Detailed knowledge of industry needs, “pain” and costs Product & market expertise Credibility with investment community to raise funds on public markets Credibility with target markets where brand names sign on publicly
8. Collaborations Give & Take with Tier 1 & Tier 2 Partners Strong base of intellectual property Exclusivity of testing for specific products/regions/timeframe Public collaboration announcements Investor confidence & increasing levels of financing Cash for in-house technology development Ownership of all IP Grant exclusive licenses for royalties
9. Open Innovation Lessons learned – the bad news first Important to establish clear property rights before or at first meeting Everything takes longer than you think, esp. with large companies Smaller companies may not have the horsepower or experience needed to bring products to market Confidential agreement terms difficult for investors (but good for us)
10. Open Innovation Lessons learned – now, the good news Collaboration benefits: Farm out work to external facilities/experts to reduce costs Third party technology endorsement Increase speed to market with internal champions at multinationals Assistance with regulatory approval process Help design best machine to meet industry needs (batch vs continuous, size, processing speed, necessary savings to justify investment) So far, no regrets. Each collaboration has served a valuable purpose and we learn from every one.
11. Open Innovation Selected examples Aridis Pharmaceuticals – Early credibility with investors, learned about sector, provided prototype design input, too small for larger collaboration DaniscoAS – First global collaboration, great partner, good credibility Bioseutica PLC – Good signal to huge market in encapsulation Nestlé SA – Best possible reference in food industry SRC – Detailed feedback on design, help us keep costs low
12. Contact Details Jennifer Thompson V.P. Corporate Development & Investor Relations P: (604) 603-6549 E: jthompson@enwave.net www.enwave.net | TSX-V: ENW | FSE: E4U